STA
RVMD icon

Summit Trail Advisors’s Revolution Medicines RVMD Stock Holding History

Summit Trail Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42M Buy
7,559
+83
+1% +$12.1K 0.02% 828
2026
Q1 		$727K Buy
7,476
+1,615
+28% +$163K 0.01% 1042
2025
Q4 		$467K Buy
5,861
+1,357
+30% +$89K 0.01% 1099
2025
Q3 		$210K Buy
+4,504
New +$176K ﹤0.01% 1285

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Summit Trail Advisors's RVMD Position: Q2 2026 in Review

Summit Trail Advisors increased its Revolution Medicines (RVMD) stake by 1.1% in Q2 2026, buying an estimated $12.1K and bringing the position to 7,559 shares worth $1.42M. The position accounts for 0.02% of the portfolio, ranked #828.

Summit Trail Advisors first reported a position in RVMD in Q3 2025 and has held it in 4 quarters since. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Summit Trail Advisors held 7,559 shares of Revolution Medicines worth $1.42M as of Q2 2026.
  • Summit Trail Advisors bought 83 Revolution Medicines shares in Q2 2026, an estimated $12.1K.
  • Revolution Medicines made up 0.02% of Summit Trail Advisors's portfolio in Q2 2026, its #828 holding.
  • Summit Trail Advisors first reported a position in Revolution Medicines in Q3 2025 and has held it in 4 quarters since.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.